By Berlanga H.B. No. 2571
75R7055 JMM-F
A BILL TO BE ENTITLED
1-1 AN ACT
1-2 relating to the substitution of certain drugs by a pharmacist.
1-3 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
1-4 SECTION 1. Section 40(l), Texas Pharmacy Act (Article
1-5 4542a-1, Vernon's Texas Civil Statutes), is amended to read as
1-6 follows:
1-7 (l) Drug product selection as authorized in this section
1-8 shall not apply to enteric-coated tablets; controlled release
1-9 products; injectable suspensions, other than antibiotics;
1-10 suppositories containing active ingredients for which systemic
1-11 absorption is necessary for therapeutic activity; narrow
1-12 therapeutic index drugs; and different delivery systems for
1-13 aerosol or nebulizer drugs. This subsection shall not apply to
1-14 any drug product which is determined to be generically equivalent
1-15 to the brand prescribed, except for narrow therapeutic index drugs.
1-16 The interchange of narrow therapeutic index drugs requires
1-17 specific written authorization by the prescribing physician. In
1-18 this subsection, "narrow therapeutic index drugs" means medications
1-19 defined by the federal Food and Drug Administration as having a
1-20 narrow therapeutic index, including digoxin, phenytoin, warfarin
1-21 sodium, theophylline, levothryroxine, carbamazine, valproic acid,
1-22 and lithium.
1-23 SECTION 2. This Act takes effect September 1, 1997.
1-24 SECTION 3. The importance of this legislation and the
2-1 crowded condition of the calendars in both houses create an
2-2 emergency and an imperative public necessity that the
2-3 constitutional rule requiring bills to be read on three several
2-4 days in each house be suspended, and this rule is hereby suspended.